Even more recently, the discovery of cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death-1 receptor (PD-1) as potential targets has opened the door on immuno-oncological therapies for cancer management. Here, CTLA4 is linked to cancer.